- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
John D. Shakow
News 25 results
In the News · Source: Law.com
In the News · Source: Bloomberg Law
In the News · Source: Managed Healthcare Executive
January 19, 2026
John Shakow and David Farber comment on the limitations of rebates and cost savings for health plans and patients under new Medicare drug programs
Recognition
June 11, 2025
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2025 Guide
Events 8 results
Conference
April 8, 2026
Annual California Life Sciences Summit
Webinar
January 8, 2026
Medicare and Medicaid Demos Seek To Impose Most Favored Nation Pricing: An Overview of GLOBE, GUARD, and GENEROUS
Conference
November 4, 2025
King & Spalding Pharmaceutical University 2025
Speaking Engagement
October 22, 2025
Rob DeConti, Nikki Reeves, John Shakow to Speak at the 26th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress Conference
Insights 5 results
Client Alert
February 9, 2026
FTC’s “Landmark” Settlement with Pharmacy Benefit Manager Express Scripts: Impact on Pharma
Client Alert
February 2, 2026
HHS-OIG Issues Guidance on Pharma DTC Prescription Drug Sales, but Key Legal Questions Remain
Client Alert
December 29, 2025
Medicare and Medicaid Demos Seek to Impose MFN Pricing: An Overview of GENEROUS, GLOBE, and GUARD
Client Alert
November 19, 2025
2026 Physician Fee Schedule Final Rule Changes to ASP Calculation and Reporting Policies and Other Drug Payment Policies